A Tsukamoto

National Hospital Organization Kumamoto Medical Center, Kumamoto, Kumamoto, Japan

Are you A Tsukamoto?

Claim your profile

Publications (22)45.51 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: We report 2 cases of serum sickness after rituximab infusion. Case 1 is a patient with Waldenström's macroglobulinemia, and case 2 is a patient with marginal-zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type and Sjögren's syndrome. Both patients had polyclonal hypergammaglobulinemia, were treated with rituximab monotherapy, developed serum sickness between 9 and 17 days after the first rituximab infusion, developed fever and arthralgia, and improved soon after corticosteroid treatment. Serum sickness after rituximab treatment for hematological malignancies is very rare as far as we know. We identified three risk factors of serum sickness after rituximab infusion from previous reports and our cases; administration of rituximab alone, the existence of Sjögren's syndrome, and polyclonal hypergammaglobulinemia.
    [Rinshō ketsueki] The Japanese journal of clinical hematology 05/2009; 50(4):304-8.
  • [Show abstract] [Hide abstract]
    ABSTRACT: We previously reported that monotherapy with carbapenem or cefepime exhibited efficacy equivalent to cefepime plus an aminoglycoside as initial therapy for febrile neutropenia (FN), achieving an adequate response in two-thirds of the patients. However, only one-third of the remaining poor responders to monotherapy became afebrile after an aminoglycoside was added to the initial carbapenem or cefepime. The present study was designed to evaluate the benefit of intravenous ciprofloxacin for neutropenic patients with fever who were refractory to initial therapy given for the first 3 days. Patients with FN--as defined by an axillary temperature >or=37.5 degrees C and a neutrophil count <1,000/microL-who had no response to initial therapy with carbapenem or cefepime for 72 hours were to receive additional ciprofloxacin 600 mg/day. They were otherwise managed according to the Japanese guidelines for FN. An adequate response was defined as a decline of temperature to <37.5 degrees C within 7 days after initiation of ciprofloxacin treatment. Thirty-one patients with FN (seventeen male and fourteen female; mean age 53.1 +/- 14.8 years) were entered in the study. The initial antibiotics were cefepime (2 - 4 g/day) in twenty and carbapenem (1 - 2 g/day) in eleven. Three patients were excluded from analysis, leaving 28 patients for evaluation of efficacy. The response rate was 16/31 patients (51.6%),with four patients judged non-assessable due to adverse effects, protocol violation or early change to other agents. Adverse events occurred in seventeen patients, but all were mild and reversible. Only three patients had adverse events (skin rash, hepatic dysfunction and elevation of alkaline phosphatase in one patient, respectively) considered related to ciprofloxacin. These findings indicate that addition of intravenous ciprofloxacin is effective against FN refractory to initial antibiotic therapy and has acceptable toxicity.
    Leukemia and Lymphoma 08/2006; 47(8):1618-23. DOI:10.1080/10428190600572731 · 2.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patients with hematological malignancies who relapse after bone marrow transplantation (BMT) are often treated with donor lymphocyte infusion. However, this procedure often results in graft-versus-host disease (GVHD). While, Dendritic cells (DCs), which present antigens to naive T cells, have been used in the immunotherapy of cancer, this approach has been logistically difficult due to limiting numbers of DCs. We have now developed a method for obtaining a large number of DCs by treating the granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cells (PBSCs) from healthy donors with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4), and tumor necrosis factor-alpha (TNF-alpha). The resulting cells possess the morphologic, phenotypic, and functional characteristics of mature DCs. In in vitro studies, culture of these HLA-matched donor derived-DCs with irradiated each patient's tumor cells as an antigen source, followed by incubation with T cells from the patient, induced the production of highly cytotoxic T lymphocytes (CTLs) specific for the respective tumor cells in the semi-allogeneic setting. A transient, but objective clinical response was obtained in the absence of GVHD when we injected the DCs which had been pulsed with irradiated tumor cells as well as primed T cells from the same original donor of related- allogeneic stem cell transplantation into the relapsed patients. Our findings suggest that treatment of relapsed patients with such donor-derived DCs, and primed T cells may be effective as an adjunctive immunotherapy.
    Leukemia and Lymphoma 08/2001; 42(3):357-69. DOI:10.3109/10428190109064592 · 2.89 Impact Factor
  • I Sanada · F Kawano · A Tsukamoto · T Kiyokawa ·
    [Show abstract] [Hide abstract]
    ABSTRACT: A 24-year-old woman was followed for about ten months with oral administration of prednisolone (22.5-35 mg/d) for autoimmune hepatitis. In June 1995, she noticed fatigue and appetite loss and blood chemistry revealed markedly deteriorated liver function. She was admitted to our hospital. The daily dose of prednisolone was increased to 60 mg. Her elevated levels of transaminases decreased gradually. Administration of azathioprine (100 mg/d) was started with tapering of prednisolone on August 18th. Ten days later, tender cervical lymphadenopathy and high fever occurred. Azathioprine administration was stopped immediately and intravenous antibiotics were given. On September 5th, 50 mg of azathioprine was administered again. Two hours later, the patient complained of intolerable pain from the lumbar region to the knee joints, which subsided following two injections of analgesics within a few hours. However, chills, high fever and hypotension (86/30 mmHg) subsequently developed. No bacterial growth was detected in blood culture. She was discharged on September 12th. On October 4th, she visited our out-patient clinic. The next day, she took one tablet (50 mg) of azathioprine at 10 o'clock. She noted intense pain from the thighs to the knees and calves around noon again. Her home doctor found that she exhibited shock (BP 67/?). She was immediately taken to our department. The same symptoms and signs as the above-mentioned occurred. Azathioprine was considered responsible for these two adverse reactions (shock) as an allergen. Later, systemic lupus eythematosus was diagnosed in 1996. And she died to pulmonary hypertension in May 1999. Physicians should be aware of the potential adverse effect of azathioprine administered in order to manage the patients with autoimmune disorders.
    Japanese Journal of Clinical Immunology 05/2000; 23(2):129-34. DOI:10.2177/jsci.23.129
  • F. Kawano · I. Sanada · A. Tsukamoto · T. Kiyokawa · S. Uneda · M. Matsuoka · H. Mitsuya ·

    Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 04/1999; 20(4):A60. DOI:10.1097/00042560-199904010-00223
  • I. Sanada · F. Kawano · A. Tsukamoto · T. Kiyokawa ·

    Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 04/1999; 20(4):A60. DOI:10.1097/00042560-199904010-00222
  • I Sanada · F Kawano · A Tsukamoto · T Kiyokawa ·
    [Show abstract] [Hide abstract]
    ABSTRACT: We report on two adult T-cell leukemia (ATL) patients whose levels of serum hyaluronic acid (HA) moved in parallel with the clinical activity of their disease. A 66-year-old man was admitted to our hospital because of unconsciousness and hypotension. Acute type ATL complicated by hypercalcemia and myelofibrosis was diagnosed. Before therapy, the level of patient's serum HA was 2,045 to 4,010 ng/ml (normal range: 50 >). After he achieved complete remission (CR) through chemotherapy, his serum HA was 36 ng/ml. Several months later, however, his ATL relapsed, and his serum HA increased to 393 ng/ml. The other patient was an 80-year-old man who had been admitted on the suspected diagnosis of ATL. Before chemotherapy, his serum HA was high (3,420 ng/ml). After CHOP therapy, he entered CR and his HA decreased to 122 ng/ml. He remains in CR with slightly elevated levels of HA (127 to 212 ng/ml), and is being followed up on an out-patient basis.
    [Rinshō ketsueki] The Japanese journal of clinical hematology 01/1999; 40(1):51-4.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Thirty patients (median age of 32 years; range, 6-61) with hematologic disorders received unmanipulated peripheral blood stem cell transplants from HLA-matched or one-antigen-mismatched related donors following myeloablative therapy for acute lymphoblastic leukemia (7), acute myelogenous leukemia (6), chronic myelogenous leukemia (8), myelodysplastic syndrome (3), or other disorders (6). Granulocyte colony stimulating factor (G-CSF) mobilized peripheral blood stem cells were collected from donors in 1 to 3 aphereses. The apheresis products contained mean counts of 11.3 x 10(8) (range, 3.8-17.2) nucleated cells/kg and 6.7 x 10(6) (range, 1.3-16.7) CD34+ cells/kg. Graft-versus-host-disease (GVHD) prophylaxis consisted of cyclosporin A plus methotrexate, or FK506 plus methotrexate. All patients received G-CSF following their transplant. Although 1 patient died of pneumonia 6 days after transplantation, the others demonstrated rapid engraftment. Median days to recovery to 500/microliter neutrophils and 20,000/microliter platelets were 13 (range, 8-21) and 14 (range, 1-23) days, respectively. The incidence of acute GVHD grade II-IV was 33%; chronic GVHD developed in 57% of the assessable patients. There were no episodes of graft failure or rejection. Nineteen patients (63%) were alive and in complete remission from 147 to 839 days following their transplant (median follow-up of 560 days). Further follow-up study will be required to assess the incidence of chronic GVHD and graft-versus-leukemia (GVL) effects.
    [Rinshō ketsueki] The Japanese journal of clinical hematology 12/1998; 39(11):1085-91.
  • I Sanada · F Kawano · A Tsukamoto · T Kiyokawa · T Shido · S Koga ·
    [Show abstract] [Hide abstract]
    ABSTRACT: We report a 82-year-old woman with adult onset Still's disease (AOSD), who presented with high fever, skin rash, swollen axillary lymph nodes, accelerated erythrocyte sedimentation rate, leukocytosis, abnormal liver function tests, hypoalbuminemia, negative antinuclear antibody and rheumatoid factor, and lack of renal involvement. Disseminated intravascular coagulation (DIC) was also diagnosed on admission. An antipyretic relieved high fever and DIC soon improved. Three years later, AOSD relapsed accompanied by hypercoagulation and hyperfibrinolysis. The patient developed subdural hematoma and DIC due to a brain contusion. High titers of serum soluble adhesion molecules and soluble thrombomodulin were noted on the first episode of DIC. These findings indicated that endothelial cells were damaged in AOSD complicated by DIC.
    [Rinshō ketsueki] The Japanese journal of clinical hematology 12/1997; 38(11):1194-8.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We investigated 34 cases of T-cell neoplasm [15 cases of T-cell granular lymphocytic leukemia (T-GLL), 10 cases of T-cell non-Hodgkin's lymphoma (T-NHL), six cases of T-cell chronic lymphocytic leukemia (T-CLL), and three cases of cutaneous T-cell lymphoma] to study their association with Epstein-Barr virus (EBV). In 4 (three T-NHL and one T-GLL) of 34 cases, EBV genome was detected in a single episomal form, while polyclonal EBV-DNA was detected in one (T-NHL) of the remaining cases. All three cases of T-NHL having monoclonal EBV episome showed histologically diffuse large-cell lymphoma and developed leukemic conversion. Phenotypic analysis showed that two of these four cases were CD4+, CD8-, and the remaining two cases were CD4-, CD8+. The cells from all four cases were confirmed to be in T-cell lineage by detecting the rearrangement of T-cell receptor (TCR) beta or gamma chain gene. By reverse transcription-polymerase chain reaction (RT-PCR), EBNA-1 was detected at low levels, and neither EBNA-2 nor LMP-1 were found in any of the three cases examined. Lack of the expression of EBNA-2 and LMP-1 was also confirmed by immunocytochemical staining. The cells of these four cases did not show rearrangement or overexpression of c-myc and bcl-2 genes by Southern and Northern blots, and the mutation of p53 gene was detected in only one patient. These results suggest that other latent gene products of EBV or other cellular oncogenes are involved in the development of Japanese T-cell neoplasm after EBV infection.
    Blood 02/1995; 85(2):480-6. · 10.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We report a patient with acute myelogenous leukemia [AML, French-American-British classification (FAB) M2] with trisomy 4, who developed subcutaneous soft tissue tumors at the time leukemia was diagnosed. A review of the literature on AML with trisomy 4 suggests a relation between trisomy 4 and tumor formation of leukemic cells.
    Cancer Genetics and Cytogenetics 12/1993; 71(1):71-5. DOI:10.1016/0165-4608(93)90204-Y · 1.93 Impact Factor
  • Y Sone · F Kawano · Y Nishimura · H Kurisaki · A Tsukamoto · T Kiyokawa · I Sanada · T Shido ·
    [Show abstract] [Hide abstract]
    ABSTRACT: A 45-year-old woman with Bence-Jones type multiple myeloma was treated with natural type alpha-interferon (Namalwa interferon), 3 million IU every other day subcutaneously. After about 5 months, she developed hemolytic anemia. However, screening tests for autoantibodies, including direct and indirect antiglobulin (Coombs' tests), were negative. This report is the first case in which hemolytic anemia appeared to be caused by natural type alpha-interferon. It is likely that interferons will be used in treating increasing numbers of patients and that more patients will develop this complication.
    [Rinshō ketsueki] The Japanese journal of clinical hematology 06/1993; 34(5):670-2.
  • A Tsukamoto · F Kawano · M Satoh · I Sanada · T Shido ·

    American Journal of Hematology 01/1993; 41(4):306. · 3.80 Impact Factor
  • Atsuko Tsukamoto · Fumio Kawano · Masahiko Satoh · Isao Sanada · Tadahiro Shido ·

    American Journal of Hematology 12/1992; 41(4):306-306. DOI:10.1002/ajh.2830410427 · 3.80 Impact Factor
  • F Kawano · K Nishida · H Kurisaki · A Tsukamoto · M Satoh · I Sanada · T Shido · S Obata · K Kimura · Y Sasaki ·
    [Show abstract] [Hide abstract]
    ABSTRACT: An adult T cell leukemia (ATL) accompanied with Isospora belli infection was described. A 65-year-old male was admitted to our hospital because of a two month history of watery diarrhea. On admission, physical examination showed slight pallor but no detectable superficial lymphadenopathies. Hepatosplenomegaly was not observed. Laboratory examination revealed a leukocyte count 5,500/microliters with 10% abnormal lymphoid cells. A majority of the abnormal lymphoid cells expressed both CD 4 and CD 8 antigens. The patient was diagnosed as chronic ATL, since anti-HTLV-1 antibody in his serum and monoclonal integration of HTLV-1 proviral DNA in his peripheral mononuclear cells were detected. Isospora belli was found in his feces thereafter, and trimethoprim/sulfamethoxazole was effective for diarrhea. In Japan, there have been only 9 reported cases of lymphoproliferative disorders (including five ATL patients) accompanied with Isospora belli infection. From the descriptions in those reports, these 9 cases might all be ATL patients.
    [Rinshō ketsueki] The Japanese journal of clinical hematology 06/1992; 33(5):683-7.
  • F Kawano · Y Nishimura · A Tsukamoto · M Satoh · I Sanada · T Shido ·

    International Journal of Hematology 03/1992; 55(1):101-2. · 1.92 Impact Factor
  • F Kawano · A Tsukamoto · M Satoh · I Sanada · T Shido · H Suzushima · N Asou · K Takatsuki ·

    Leukemia 02/1992; 6(1):66-7. · 10.43 Impact Factor
  • F Kawano · A Tsukamoto · M Satoh · I Sanada · T Shido · K Miura · T Murakami · H Kaneko · M Takeya · H Matsuzaki ·
    [Show abstract] [Hide abstract]
    ABSTRACT: A 78-year-old man was admitted because of lumbago and chest pain. A diagnosis of non-secretory primary plasma cell leukemia was made based on the laboratory findings and his history. However, the plaque-forming cells assay of bone marrow cells revealed secretion of monoclonal immunoglobulin from the myeloma cells. Hyperammonemia was detected in the serum. Although the patient was treated with 4 courses of combination chemotherapy (vincristine, adriamycin, cyclophosphamide, methylprednisolone), he died of respiratory failure five months after diagnosis. Autopsy showed widespread multiple myeloma and prominent infiltration of myeloma cell in the sinusoid of the liver. Recently, there have been a few reports which increased the plasma ammonia concentration with multiple myeloma. This report strongly suggested that liver infiltration of myeloma cell caused hyperammonemia.
    [Rinshō ketsueki] The Japanese journal of clinical hematology 05/1991; 32(4):399-403.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Histocompatibility antigens (HLA-A,B,C,DR, and DQ antigens) were investigated in 25 Japanese patients with the Crow-Fukase syndrome (Takatsuki's disease). No significant associations were detected between the patients with the Crow-Fukase syndrome and the healthy controls.
    Clinical Immunology and Immunopathology 10/1990; 56(3):420-2. DOI:10.1016/0090-1229(90)90161-I
  • S Obata · A Tsukamoto · K Kimura · K Maeda · R Kawamura ·
    [Show abstract] [Hide abstract]
    ABSTRACT: A patient with gastric involvement of adult T-cell leukemia is reported. Endoscopically, it mimicked an early gastric cancer IIa + IIc, but had the nature of a submucosal tumor, and could be distinguished from carcinoma. It is very important to distinguish it from carcinoma because of the different mode of therapy.
    Endoscopy 04/1990; 22(2):81-2. DOI:10.1055/s-2007-1012799 · 5.05 Impact Factor

Publication Stats

98 Citations
45.51 Total Impact Points


  • 1989-2006
    • National Hospital Organization Kumamoto Medical Center
      Kumamoto, Kumamoto, Japan
  • 1995
    • Kumamoto University
      • School of Medicine
      Kumamoto, Kumamoto, Japan